Open Trial of Bupropion SR in Adolescent Major Depression

doi:10.1111/j.1744-6171.2003.00123.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

Journal of Child and Adolescent Psychiatric Nursing

Volume 16 Issue 3, Pages 123 - 130

Published Online: 25 Aug 2004

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

Abstract | References | Full Text: PDF (Size: 120K) | Related Articles | Citation Tracking

Open Trial of Bupropion SR in Adolescent Major Depression

Carol A. Glod, PhD, RN, FAAN ¹ , Arlene Lynch, MS, RN, CS ² , Elizabeth Flynn, APRN ³ , Cynthia Berkowitz, MD ⁴ , Ross J. Baldessarini, MD ⁵

¹ Associate Professor, Bouvé College of Health Sciences, Northeastern University, Boston, MA, and Lecturer, Harvard Medical School, Department of Psychiatry, Belmont, MA ² Family Nurse Practitioner, McLean Hospital, Belmont, MA ³ Psychiatric Nurse Practitioner in private practice, Londonderry, NH ⁴ Child psychiatrist, The Walker School, Needham, MA ⁵ Professor, Harvard Medical School, Department of Psychiatry, and Director, Bipolar & Psychotic Disorders Program, McLean Hospital, Belmont, MA

Correspondence to Author contact: DrGlod@aol.com, with a copy to the Editor: Poster@uta.edu

KEYWORDS

Adolescents • bupropion SR • major depressive disorder

ABSTRACT

There are few studies of sustained-release bupropion in adolescents with major depression.

METHODS

Twenty-one adolescents with DSM-IV major depression were recruited through advertisement and self-referral; 11 began study medication and were rated weekly with an expanded Hamilton Depression Rating Scale (SIGH-SAD), as well as Clinical Global Impression-Improvement (CGI-I).

RESULTS

Of 11 subjects enrolled, 8 completed an8-week trial of bupropion SR. Mean baseline SIGH-SAD scores of 31–3 decreased significantly by 74% to mean endpoint score of 8–2. Improvement on CGI-I that agreed closely between raters and patients was found in 8 of 11 subjects (72.3%). The mean daily dose of bupropion SR was 362 mg ± 52 mg and was well tolerated; insomnia and weight loss were experienced by 55%; other adverse effects of dry mouth, headache, agitation, light-headedness, diarrhea, or rash were noted in a minority of subjects.